Cargando…

Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel

BACKGROUND: Pulmonary sequelae (PS) in patients with chronic paracoccidioidomycosis (PCM) typically include pulmonary fibrosis and emphysema. Knowledge of the molecular pathways involved in PS of PCM is required for treatment and biomarker identification. METHODOLOGY/PRINCIPAL FINDINGS: This non-con...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Santos, Amanda Ribeiro, Dionizio, Aline, Fernandes, Mileni da Silva, Buzalaf, Marília Afonso Rabelo, Pereira, Beatriz, Donanzam, Débora de Fátima Almeida, Ribeiro, Sergio Marrone, Paniago, Anamaria Mello Miranda, Cavalcante, Ricardo de Souza, Mendes, Rinaldo Poncio, Venturini, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425554/
https://www.ncbi.nlm.nih.gov/pubmed/34424905
http://dx.doi.org/10.1371/journal.pntd.0009714
_version_ 1783749869869989888
author dos Santos, Amanda Ribeiro
Dionizio, Aline
Fernandes, Mileni da Silva
Buzalaf, Marília Afonso Rabelo
Pereira, Beatriz
Donanzam, Débora de Fátima Almeida
Ribeiro, Sergio Marrone
Paniago, Anamaria Mello Miranda
Cavalcante, Ricardo de Souza
Mendes, Rinaldo Poncio
Venturini, James
author_facet dos Santos, Amanda Ribeiro
Dionizio, Aline
Fernandes, Mileni da Silva
Buzalaf, Marília Afonso Rabelo
Pereira, Beatriz
Donanzam, Débora de Fátima Almeida
Ribeiro, Sergio Marrone
Paniago, Anamaria Mello Miranda
Cavalcante, Ricardo de Souza
Mendes, Rinaldo Poncio
Venturini, James
author_sort dos Santos, Amanda Ribeiro
collection PubMed
description BACKGROUND: Pulmonary sequelae (PS) in patients with chronic paracoccidioidomycosis (PCM) typically include pulmonary fibrosis and emphysema. Knowledge of the molecular pathways involved in PS of PCM is required for treatment and biomarker identification. METHODOLOGY/PRINCIPAL FINDINGS: This non-concurrent cohort study included 29 patients with pulmonary PCM that were followed before and after treatment. From this group, 17 patients evolved to mild/ moderate PS and 12 evolved severe PS. Sera from patients were evaluated before treatment and at clinical cure, serological cure, and apparent cure. A nanoACQUITY UPLC-Xevo QT MS system and PLGS software were used to identify serum differentially expressed proteins, data are available via ProteomeXchange with identifier PXD026906. Serum differentially expressed proteins were then categorized using Cytoscape software and the Reactome pathway database. Seventy-two differentially expressed serum proteins were identified in patients with severe PS compared with patients with mild/moderate PS. Most proteins altered in severe PS were involved in wound healing, inflammatory response, and oxygen transport pathways. Before treatment and at clinical cure, signaling proteins participating in wound healing, complement cascade, cholesterol transport and retinoid metabolism pathways were downregulated in patients with severe PS, whereas signaling proteins in gluconeogenesis and gas exchange pathways were upregulated. At serological cure, the pattern of protein expression reversed. At apparent cure pathways related with tissue repair (fibrosis) became downregulated, and pathway related oxygen transport became upregulated. Additionally, we identified 15 proteins as candidate biomarkers for severe PS. CONCLUSIONS/SIGNIFICANCE: Development of severe PS is related to increased expression of proteins involved in glycolytic pathway and oxygen exchange), indicative of the greater cellular activity and replication associated with early dysregulation of wound healing and aberrant tissue repair. Our findings provide new targets to study mechanisms of PS in PCM, as well as potential biomarkers.
format Online
Article
Text
id pubmed-8425554
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84255542021-09-09 Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel dos Santos, Amanda Ribeiro Dionizio, Aline Fernandes, Mileni da Silva Buzalaf, Marília Afonso Rabelo Pereira, Beatriz Donanzam, Débora de Fátima Almeida Ribeiro, Sergio Marrone Paniago, Anamaria Mello Miranda Cavalcante, Ricardo de Souza Mendes, Rinaldo Poncio Venturini, James PLoS Negl Trop Dis Research Article BACKGROUND: Pulmonary sequelae (PS) in patients with chronic paracoccidioidomycosis (PCM) typically include pulmonary fibrosis and emphysema. Knowledge of the molecular pathways involved in PS of PCM is required for treatment and biomarker identification. METHODOLOGY/PRINCIPAL FINDINGS: This non-concurrent cohort study included 29 patients with pulmonary PCM that were followed before and after treatment. From this group, 17 patients evolved to mild/ moderate PS and 12 evolved severe PS. Sera from patients were evaluated before treatment and at clinical cure, serological cure, and apparent cure. A nanoACQUITY UPLC-Xevo QT MS system and PLGS software were used to identify serum differentially expressed proteins, data are available via ProteomeXchange with identifier PXD026906. Serum differentially expressed proteins were then categorized using Cytoscape software and the Reactome pathway database. Seventy-two differentially expressed serum proteins were identified in patients with severe PS compared with patients with mild/moderate PS. Most proteins altered in severe PS were involved in wound healing, inflammatory response, and oxygen transport pathways. Before treatment and at clinical cure, signaling proteins participating in wound healing, complement cascade, cholesterol transport and retinoid metabolism pathways were downregulated in patients with severe PS, whereas signaling proteins in gluconeogenesis and gas exchange pathways were upregulated. At serological cure, the pattern of protein expression reversed. At apparent cure pathways related with tissue repair (fibrosis) became downregulated, and pathway related oxygen transport became upregulated. Additionally, we identified 15 proteins as candidate biomarkers for severe PS. CONCLUSIONS/SIGNIFICANCE: Development of severe PS is related to increased expression of proteins involved in glycolytic pathway and oxygen exchange), indicative of the greater cellular activity and replication associated with early dysregulation of wound healing and aberrant tissue repair. Our findings provide new targets to study mechanisms of PS in PCM, as well as potential biomarkers. Public Library of Science 2021-08-23 /pmc/articles/PMC8425554/ /pubmed/34424905 http://dx.doi.org/10.1371/journal.pntd.0009714 Text en © 2021 Santos et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
dos Santos, Amanda Ribeiro
Dionizio, Aline
Fernandes, Mileni da Silva
Buzalaf, Marília Afonso Rabelo
Pereira, Beatriz
Donanzam, Débora de Fátima Almeida
Ribeiro, Sergio Marrone
Paniago, Anamaria Mello Miranda
Cavalcante, Ricardo de Souza
Mendes, Rinaldo Poncio
Venturini, James
Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel
title Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel
title_full Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel
title_fullStr Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel
title_full_unstemmed Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel
title_short Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel
title_sort proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425554/
https://www.ncbi.nlm.nih.gov/pubmed/34424905
http://dx.doi.org/10.1371/journal.pntd.0009714
work_keys_str_mv AT dossantosamandaribeiro proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT dionizioaline proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT fernandesmilenidasilva proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT buzalafmariliaafonsorabelo proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT pereirabeatriz proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT donanzamdeboradefatimaalmeida proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT ribeirosergiomarrone proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT paniagoanamariamellomiranda proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT cavalcantericardodesouza proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT mendesrinaldoponcio proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel
AT venturinijames proteomicanalysisofserumsamplesofparacoccidioidomycosispatientswithseverepulmonarysequel